Mizuho Securities Downgrades Tenet Healthcare (THC) to Underperform; High Leverage
- Wall Street flat as countdown to Trump's swearing-in begins
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
- CP's (CP) Outgoing CEO Hunter Harrison, Activist Paul Hilal Said Set to Target CSX Corp. (CSX)
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Mizuho Securities downgraded Tenet Healthcare (NYSE: THC) from Neutral to Underperform with a price target of $13.00, citing high leverage.
Analyst Sheryl Skolnick commented, "THC presents a problem because of its high leverage. There, even at $13, the stock trades at 7.8x our 2016 estimate and 7.3x our 2017 estimate of EBITDA less NCI. At its current $17 price, THC trades at 7.6x multiple, i.e., a premium to HCA and that is not right under any circumstances (HCA has FCF, THC doesn’t) in our view. To be within 10% of the current stock price, i.e., to keep our Neutral rating, THC shares would have to trade at $15, i.e., at a 7.8x multiple, a nearly half-turn premium to our HCA target price. Frankly, with our work in Exhibit 11 showing that a 7.3x multiple on a 2017 year less the ACA impact mitigated by 50% gets to a $13 price target, we’re sticking to our guns on valuation work and lowering our rating on THC to Underperform. There’s just too much risk to pay a premium in our view."
Shares of Tenet Healthcare closed at $17.01 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Autoliv, Inc. (ALV) to Hold
- Goldman Sachs Downgrades Host Hotels (HST) to Sell
- Citi Downgrades AK Steel (AKS) to Sell
Create E-mail Alert Related CategoriesAnalyst Comments, Downgrades, Hot Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!